NOVEL SULFONAMIDE DERIVATIVE HAVING INHIBITORY EFFECT ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION

Title:

NOVEL SULFONAMIDE DERIVATIVE HAVING INHIBITORY EFFECT ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION

Document Type and Number:

WIPO Patent Application WO/2019/190259

Kind Code:

A1

Abstract:

The present invention relates to the compound represented by the following chemical formula 1, or a pharmaceutical composition for prevention or treatment of cancer having EGFR mutation, the composition comprising the compound and a pharmaceutically acceptable carrier: [chemical formula I].

More Like This:

JP4390457	Metalloproteinase inhibitor
WO/2002/004429	PYRIMIDINE DERIVATIVES
WO/2007/035372	POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR

Inventors:

JANG SUN YOUNG (KR)
KIM MI RA (KR)
JEON JI YOUNG (KR)
KWAK EUN JOO (KR)
LEE SUN HOE (KR)

Application Number:

PCT/KR2019/003697

Publication Date:

October 03, 2019

Filing Date:

March 29, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

HANMI PHARM IND CO LTD (KR)

International Classes:

C07D401/04; A61K31/18; A61K31/506; A61P35/00; C07D403/14

Domestic Patent References:

WO2016201370A1

2016-12-15

Foreign References:

US20110130401A1	2011-06-02
US20110098288A1	2011-04-28
KR20120047208A	2012-05-11

Other References:

CHOE, H. ET AL.: "Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 38, 2017, pages 1353 - 1357, XP055561541, doi:10.1002/bkcs.11287

Attorney, Agent or Firm:

Y.P.LEE, MOCK & PARTNERS (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD FOR PERFORMING SIDELINK COMMUNICATION ON BASIS OF POLAR CODE AND DEVICE THEREFOR

Next Patent: APPARATUS FOR DETECTING DEFROSTING TIME